AstraZeneca

Financial Performance Investment Expansion Investments Technology Advancements Vaccine Development Investment Decisions Acquisition Merger Vaccine Work Costs Products Growth Strategy Vaccine Withdrawal New Medicines

3 ARTICLES

last mo.

AstraZeneca Commits $2.5 Billion to Beijing R&D Hub in Strategic China Expansion

The investment includes partnerships with local biotech firms and government entities as the company works to rebuild its presence in its second-largest market.

5 ARTICLES

3mo ago

AstraZeneca to Acquire Icosavax for $1.1 Billion

AstraZeneca

AstraZeneca Commits $2.5 Billion to Beijing R&D Hub in Strategic China Expansion

AstraZeneca Reports Strong 2024 Results While Facing China Tax Probe

AstraZeneca Cancels £450m UK Vaccine Plant Expansion Over Funding Dispute

AstraZeneca Faces Turmoil Amid Chinese Investigations

FDA Approves First At-Home Nasal Spray Flu Vaccine

AstraZeneca Targets $80 Billion Revenue by 2030 with 20 New Medicines

AstraZeneca Projects Strong Growth in 2024 Despite COVID-19 Sales Dip

AstraZeneca to Acquire Icosavax for $1.1 Billion